{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:15:34Z","timestamp":1790709334237,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"izkf","award":["IZKF TN1-9"],"award-info":[{"award-number":["IZKF TN1-9"]}]},{"name":"izkf","award":["532009"],"award-info":[{"award-number":["532009"]}]},{"DOI":"10.13039\/501100001659","name":"deutsche forschungsgemeinschaft","doi-asserted-by":"crossref","award":["DO 2386\/1-1"],"award-info":[{"award-number":["DO 2386\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hereditary transthyretin (TTR) amyloidosis (ATTRv) is an autosomal dominant, systemic disease transmitted by amyloidogenic mutations in the\n                    <jats:italic>TTR<\/jats:italic>\n                    gene. To prevent the otherwise fatal disease course, TTR stabilizers and mRNA silencing antisense drugs are currently approved treatment options. With 90% of the amyloidogenic protein produced by the liver, disease progression including polyneuropathy and cardiomyopathy, the two most prominent manifestations, can successfully be halted by hepatic drug targeting or\u2014formerly\u2014liver transplantation. Certain\n                    <jats:italic>TTR<\/jats:italic>\n                    variants, however, favor disease manifestations in the central nervous system (CNS) or eyes, which is mostly associated with TTR production in the choroid plexus and retina. These compartments cannot be sufficiently reached by any of the approved medications. From liver-transplanted patients, we have learned that with longer lifespans, such CNS manifestations become more relevant over time, even if the underlying\n                    <jats:italic>TTR<\/jats:italic>\n                    mutation is not primarily associated with such. Are we therefore creating a new phenotype? Prolonging life will most likely lead to a shift in the phenotypic spectrum, enabling manifestations like blindness, dementia, and cerebral hemorrhage to come out of the disease background. To overcome the first therapeutic limitation, the blood\u2013brain barrier, we might be able to learn from other antisense drugs currently being used in research or even being approved for primary neurodegenerative CNS diseases like spinal muscular atrophy or Alzheimer\u2019s disease. But what effects will unselective CNS TTR knock-down have considering its role in neuroprotection? A potential approach to overcome this second limitiation might be allele-specific targeting, which is, however, still far from clinical trials. Ethical standpoints underline the need for seamless data collection to enable more evidence-based decisions and for thoughtful consenting in research and clinical practice. We conclude that the current advances in treating ATTRv amyloidosis have become a meaningful example for mechanism-based treatment. With its great success in improving patient life spans, we will still have to face new challenges including shifts in the phenotype spectrum and the ongoing need for improved treatment precision. Further investigation is needed to address these closed barriers and open questions.\n                  <\/jats:p>","DOI":"10.1186\/s42466-021-00155-8","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T21:02:57Z","timestamp":1635714177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis"],"prefix":"10.1186","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5320-9807","authenticated-orcid":false,"given":"Maike F.","family":"Dohrn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karmele R.","family":"Olaciregui Dague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Hund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"issue":"12","key":"155_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"V Plant\u00e9-Bordeneuve","year":"2011","unstructured":"Plant\u00e9-Bordeneuve, V., & Said, G. (2011). Familial amyloid polyneuropathy. Lancet Neurology, 10(12), 1086\u20131097.","journal-title":"Lancet Neurology"},{"issue":"7","key":"155_CR2","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","volume":"87","author":"P Westermark","year":"1990","unstructured":"Westermark, P., et al. (1990). Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proceedings of the National Academy of Sciences of the United States of America, 87(7), 2843\u20132845.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"155_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/jnnp-2014-308107","volume":"86","author":"L Maia","year":"2015","unstructured":"Maia, L., et al. (2015). CNS involvement in V30M transthyretin amyloidosis: Clinical, neuropathological and biochemical findings. Journal of Neurology, Neurosurgery and Psychiatry, 86(2), 159.","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"2","key":"155_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3109\/13506129.2015.1015678","volume":"22","author":"JM Beirao","year":"2015","unstructured":"Beirao, J. M., et al. (2015). Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: A review of 513 cases. Amyloid, 22(2), 117\u2013122.","journal-title":"Amyloid"},{"issue":"4","key":"155_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/hmg\/ddi051","volume":"14","author":"ML Soares","year":"2005","unstructured":"Soares, M. L., et al. (2005). Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: Complexity in a single-gene disease. Human Molecular Genetics, 14(4), 543\u2013553.","journal-title":"Human Molecular Genetics"},{"issue":"6","key":"155_CR6","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/jnc.15233","volume":"156","author":"MF Dohrn","year":"2021","unstructured":"Dohrn, M. F., et al. (2021). Targeting transthyretin-Mechanism-based treatment approaches and future perspectives in hereditary amyloidosis. Journal of Neurochemistry, 156(6), 802\u2013818.","journal-title":"Journal of Neurochemistry"},{"issue":"5","key":"155_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/ejhg.2015.180","volume":"24","author":"D Santos","year":"2016","unstructured":"Santos, D., et al. (2016). Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M). European Journal of Human Genetics, 24(5), 756\u2013760.","journal-title":"European Journal of Human Genetics"},{"issue":"2","key":"155_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ana.25409","volume":"85","author":"D Santos","year":"2019","unstructured":"Santos, D., et al. (2019). Large normal alleles of ATXN2 decrease age at onset in transthyretin familial amyloid polyneuropathy Val30Met patients. Annals of Neurology, 85(2), 251.","journal-title":"Annals of Neurology"},{"issue":"6","key":"155_CR9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/iub.340","volume":"62","author":"MA Liz","year":"2010","unstructured":"Liz, M. A., et al. (2010). Aboard transthyretin: From transport to cleavage. IUBMB Life, 62(6), 429\u2013435.","journal-title":"IUBMB Life"},{"issue":"7","key":"155_CR10","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1172\/JCI105861","volume":"47","author":"KA Woeber","year":"1968","unstructured":"Woeber, K. A., & Ingbar, S. H. (1968). The contribution of thyroxine-binding prealbumin to the binding of thyroxine in human serum, as assessed by immunoadsorption. The Journal of Clinical Investigation, 47(7), 1710\u20131721.","journal-title":"The Journal of Clinical Investigation"},{"issue":"9","key":"155_CR11","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1172\/JCI106393","volume":"49","author":"FR Smith","year":"1970","unstructured":"Smith, F. R., Raz, A., & Goodman, D. S. (1970). Radioimmunoassay of human plasma retinol-binding protein. The Journal of Clinical Investigation, 49(9), 1754\u20131761.","journal-title":"The Journal of Clinical Investigation"},{"issue":"7","key":"155_CR12","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.36.7.900","volume":"36","author":"J Herbert","year":"1986","unstructured":"Herbert, J., et al. (1986). Transthyretin: A choroid plexus-specific transport protein in human brain. The 1986 S. Weir Mitchell award. Neurology, 36(7), 900\u2013911.","journal-title":"Neurology"},{"issue":"35","key":"155_CR13","doi-asserted-by":"publisher","first-page":"12483","DOI":"10.1523\/JNEUROSCI.2417-11.2011","volume":"31","author":"X Li","year":"2011","unstructured":"Li, X., et al. (2011). Neuronal production of transthyretin in human and murine Alzheimer\u2019s disease: Is it protective? Journal of Neuroscience, 31(35), 12483.","journal-title":"Journal of Neuroscience"},{"key":"155_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1750-1326-6-79","volume":"6","author":"X Li","year":"2011","unstructured":"Li, X., & Buxbaum, J. N. (2011). Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer\u2019s disease? Molecular Neurodegeneration, 6, 79.","journal-title":"Molecular Neurodegeneration"},{"issue":"3","key":"155_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","volume":"40","author":"G Holmgren","year":"1991","unstructured":"Holmgren, G., et al. (1991). Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clinical Genetics, 40(3), 242\u2013246.","journal-title":"Clinical Genetics"},{"issue":"8853","key":"155_CR16","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","volume":"341","author":"G Holmgren","year":"1993","unstructured":"Holmgren, G., et al. (1993). Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet, 341(8853), 1113\u20131116.","journal-title":"Lancet"},{"issue":"9","key":"155_CR17","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","volume":"99","author":"B-G Ericzon","year":"2015","unstructured":"Ericzon, B.-G., et al. (2015). Liver transplantation for hereditary transthyretin amyloidosis: After 20 years still the best therapeutic alternative? Transplantation, 99(9), 1847\u20131854.","journal-title":"Transplantation"},{"issue":"1","key":"155_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D., et al. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. The New England Journal of Medicine, 379(1), 11\u201321.","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"155_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson, M. D., et al. (2018). Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine, 379(1), 22\u201331.","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"155_CR20","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho, T., et al. (2012). Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology, 79(8), 785\u2013792.","journal-title":"Neurology"},{"issue":"11","key":"155_CR21","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer, M. S., et al. (2018). Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine, 379(11), 1007\u20131016.","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"155_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/13506129.2018.1479249","volume":"25","author":"C Monteiro","year":"2018","unstructured":"Monteiro, C., et al. (2018). Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p. TTRV50M) amyloidosis patients. Amyloid, 25(2), 120\u2013128.","journal-title":"Amyloid"},{"issue":"6","key":"155_CR23","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.3390\/ijms21062075","volume":"21","author":"T Gi\u00e3o","year":"2020","unstructured":"Gi\u00e3o, T., et al. (2020). Undiscovered roles for transthyretin: from a transporter protein to a new therapeutic target for Alzheimer\u2019s disease. International Journal of Molecular Sciences, 21(6), 2075.","journal-title":"International Journal of Molecular Sciences"},{"key":"155_CR24","doi-asserted-by":"crossref","unstructured":"Dammacco, R., et al. (2020). Amyloidosis and ocular involvement: An overview. In Seminars in ophthalmology.","DOI":"10.1080\/08820538.2019.1687738"},{"issue":"4","key":"155_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/bjo.81.4.295","volume":"81","author":"E Ando","year":"1997","unstructured":"Ando, E., et al. (1997). Ocular manifestations of familial amyloidotic polyneuropathy type I: Long term follow up. British Journal of Ophthalmology, 81(4), 295\u2013298.","journal-title":"British Journal of Ophthalmology"},{"issue":"5","key":"155_CR26","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/BF00310133","volume":"81","author":"M Ushiyama","year":"1991","unstructured":"Ushiyama, M., Ikeda, S., & Yanagisawa, N. (1991). Transthyretin-type cerebral amyloid angiopathy in type I familial amyloid polyneuropathy. Acta Neuropathologica, 81(5), 524.","journal-title":"Acta Neuropathologica"},{"issue":"4","key":"155_CR27","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1212\/WNL.47.4.988","volume":"47","author":"M Herrick","year":"1996","unstructured":"Herrick, M., et al. (1996). Massive leptomeningeal amyloidosis associated with a Val30Met transthyretin gene. Neurology, 47(4), 988.","journal-title":"Neurology"},{"issue":"6","key":"155_CR28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1046\/j.1440-1827.2001.01228.x","volume":"51","author":"N Sakashita","year":"2001","unstructured":"Sakashita, N., et al. (2001). Familial amyloidotic polyneuropathy (ATTR Val30Met) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage. Pathology International, 51(6), 476.","journal-title":"Pathology International"},{"issue":"11","key":"155_CR29","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/tri.13326","volume":"31","author":"J Vollmar","year":"2018","unstructured":"Vollmar, J., et al. (2018). Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation\u2014A prospective single-center cohort study. Transplant International, 31(11), 1207\u20131215.","journal-title":"Transplant International"},{"issue":"12","key":"155_CR30","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/lt.22174","volume":"16","author":"L Llad\u00f3","year":"2010","unstructured":"Llad\u00f3, L., et al. (2010). Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transplantation, 16(12), 1386.","journal-title":"Liver Transplantation"},{"issue":"sup1","key":"155_CR31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3109\/13506129.2011.574354065","volume":"18","author":"D Adams","year":"2011","unstructured":"Adams, D., et al. (2011). Symptomatic and proven de novo amyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients. Amyloid, 18(sup1), 174\u2013177.","journal-title":"Amyloid"},{"issue":"22","key":"155_CR32","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1056\/NEJM200506023522219","volume":"352","author":"AJ Stangou","year":"2005","unstructured":"Stangou, A. J., Heaton, N. D., & Hawkins, P. N. (2005). Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. New England Journal of Medicine, 352(22), 2356.","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"155_CR33","doi-asserted-by":"publisher","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","volume":"7","author":"R Daneman","year":"2015","unstructured":"Daneman, R., & Prat, A. (2015). The blood\u2013brain barrier. Cold Spring Harbor Perspectives in Biology, 7(1), a020412.","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"2","key":"155_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1212\/NXG.0000000000000323","volume":"5","author":"DR Scoles","year":"2019","unstructured":"Scoles, D. R., Minikel, E. V., & Pulst, S. M. (2019). Antisense oligonucleotides: A primer. Neurology Genetics, 5(2), 323.","journal-title":"Neurology Genetics"},{"issue":"11","key":"155_CR35","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmat3765","volume":"12","author":"R Kanasty","year":"2013","unstructured":"Kanasty, R., et al. (2013). Delivery materials for siRNA therapeutics. Nature Materials, 12(11), 967\u2013977.","journal-title":"Nature Materials"},{"issue":"2","key":"155_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrd2742","volume":"8","author":"KA Whitehead","year":"2009","unstructured":"Whitehead, K. A., Langer, R., & Anderson, D. G. (2009). Knocking down barriers: Advances in siRNA delivery. Nature Reviews. Drug Discovery, 8(2), 129\u2013138.","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"6","key":"155_CR37","first-page":"707","volume":"15","author":"DR Scoles","year":"2018","unstructured":"Scoles, D. R., & Pulst, S. M. (2018). Oligonucleotide therapeutics in neurodegenerative diseases. RNA Biology, 15(6), 707.","journal-title":"RNA Biology"},{"key":"155_CR38","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S., et al. (2017). Nusinersen versus sham control in infantile-onset spinal muscular atrophy. New England Journal of Medicine, 377, 1723\u20131732.","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"155_CR39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri, E., et al. (2018). Nusinersen versus sham control in later-onset spinal muscular atrophy. New England Journal of Medicine, 378(7), 625\u2013635.","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"155_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms10787","volume":"7","author":"R Sant'Anna","year":"2016","unstructured":"Sant\u2019Anna, R., et al. (2016). Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nature Communications, 7(1), 1\u201313.","journal-title":"Nature Communications"},{"issue":"6","key":"155_CR41","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s002109900168","volume":"360","author":"H Russ","year":"1999","unstructured":"Russ, H., et al. (1999). Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology, 360(6), 719\u2013720.","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"key":"155_CR42","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/febs.15339","volume":"288","author":"F Pinheiro","year":"2020","unstructured":"Pinheiro, F., et al. (2020). Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis. The FEBS Journal, 288, 310\u2013324.","journal-title":"The FEBS Journal"},{"issue":"1","key":"155_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/nmt-2018-0033","volume":"9","author":"A Kristen","year":"2019","unstructured":"Kristen, A., et al. (2019). Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegenerative Disease Management, 9(1), 5.","journal-title":"Neurodegenerative Disease Management"},{"key":"155_CR44","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2147\/DDDT.S162913","volume":"13","author":"V Mathew","year":"2019","unstructured":"Mathew, V., & Wang, A. K. (2019). Inotersen: New promise for the treatment of hereditary transthyretin amyloidosis. Drug Design, Development and Therapy, 13, 1515.","journal-title":"Drug Design, Development and Therapy"},{"issue":"3","key":"155_CR45","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00415-019-09602-8","volume":"267","author":"A Gonz\u00e1lez-Duarte","year":"2020","unstructured":"Gonz\u00e1lez-Duarte, A., et al. (2020). Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Journal of Neurology, 267(3), 703\u2013712.","journal-title":"Journal of Neurology"},{"issue":"4","key":"155_CR46","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon, S. D., et al. (2019). Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: Analysis of the APOLLO study. Circulation, 139(4), 431\u2013443.","journal-title":"Circulation"},{"key":"155_CR47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","volume":"57","author":"CF Bennett","year":"2017","unstructured":"Bennett, C. F., et al. (2017). Pharmacology of antisense drugs. Annual Review of Pharmacology and Toxicology, 57, 81\u2013105.","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"2","key":"155_CR48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000115544","volume":"22","author":"B Weisner","year":"1983","unstructured":"Weisner, B., & Roethig, H.-J. (1983). The concentration of prealbumin in cerebrospinal fluid (CSF), indicator of CSF circulation disorders. European Neurology, 22(2), 96\u2013105.","journal-title":"European Neurology"},{"issue":"2","key":"155_CR49","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1471-4159.2007.04828.x","volume":"103","author":"CE Fleming","year":"2007","unstructured":"Fleming, C. E., Saraiva, M. J., & Sousa, M. M. (2007). Transthyretin enhances nerve regeneration. Journal of Neurochemistry, 103(2), 831\u2013839.","journal-title":"Journal of Neurochemistry"},{"issue":"6","key":"155_CR50","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/j.1471-4159.2010.07047.x","volume":"115","author":"SD Santos","year":"2010","unstructured":"Santos, S. D., et al. (2010). CSF transthyretin neuroprotection in a mouse model of brain ischemia. Journal of Neurochemistry, 115(6), 1434\u20131444.","journal-title":"Journal of Neurochemistry"},{"issue":"1","key":"155_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10238-010-0103-8","volume":"11","author":"C Gao","year":"2011","unstructured":"Gao, C., et al. (2011). Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction. Clinical and Experimental Medicine, 11(1), 49\u201354.","journal-title":"Clinical and Experimental Medicine"},{"issue":"6","key":"155_CR52","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1600-0404.1988.tb03687.x","volume":"78","author":"H Riis\u00f8en","year":"1988","unstructured":"Riis\u00f8en, H. (1988). Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer\u2019s disease. Acta Neurologica Scandinavica, 78(6), 455.","journal-title":"Acta Neurologica Scandinavica"},{"issue":"4","key":"155_CR53","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1136\/jnnp.63.4.506","volume":"63","author":"J Serot","year":"1997","unstructured":"Serot, J., et al. (1997). Cerebrospinal fluid transthyretin: Aging and late onset Alzheimer\u2019s disease. Journal of Neurology, Neurosurgery and Psychiatry, 63(4), 506.","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"5","key":"155_CR54","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/j.1471-4159.2005.03478.x","volume":"95","author":"S Ranganathan","year":"2005","unstructured":"Ranganathan, S., et al. (2005). Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. Journal of Neurochemistry, 95(5), 1461.","journal-title":"Journal of Neurochemistry"},{"issue":"3","key":"155_CR55","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1468-1331.2009.02841.x","volume":"17","author":"K Schultz","year":"2010","unstructured":"Schultz, K., et al. (2010). Transthyretin as a potential CSF biomarker for Alzheimer\u2019s disease and dementia with Lewy bodies: Effects of treatment with cholinesterase inhibitors. European Journal of Neurology, 17(3), 456.","journal-title":"European Journal of Neurology"},{"key":"155_CR56","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neurobiolaging.2017.07.002","volume":"59","author":"C Silva","year":"2017","unstructured":"Silva, C., et al. (2017). Transthyretin neuroprotection in Alzheimer\u2019s disease is dependent on proteolysis. Neurobiology of Aging, 59, 10.","journal-title":"Neurobiology of Aging"},{"issue":"7","key":"155_CR57","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1073\/pnas.0712197105","volume":"105","author":"JN Buxbaum","year":"2008","unstructured":"Buxbaum, J. N., et al. (2008). Transthyretin protects Alzheimer\u2019s mice from the behavioral and biochemical effects of A\u03b2 toxicity. Proceedings of the National Academy of Sciences of the United States of America, 105(7), 2681\u20132686.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"155_CR58","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.neurobiolaging.2007.04.007","volume":"29","author":"J Brouillette","year":"2008","unstructured":"Brouillette, J., & Quirion, R. (2008). Transthyretin: A key gene involved in the maintenance of memory capacities during aging. Neurobiology of Aging, 29(11), 1721\u20131732.","journal-title":"Neurobiology of Aging"},{"key":"155_CR59","unstructured":"Habtemariam, B. A., et al. Single dose pharmacokinetics and pharmacodynamics of transthyretin targeting GalNAc-siRNA conjugate, vutrisiran, in healthy subjects. Clinical Pharmacology & Therapeutics."},{"key":"155_CR60","doi-asserted-by":"crossref","unstructured":"Khella, S., et al. (2020). Rationale and design of NEURO-TTRansform, a phase 3 study to evaluate the efficacy and safety of AKCEA-TTR-LRx (ION-682884) in Patients with hereditary transthyretin-mediated amyloid polyneuropathy (2240). AAN Enterprises.","DOI":"10.1212\/WNL.94.15_supplement.2240"},{"key":"155_CR61","unstructured":"Esrick, E. B., et al., Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. New England Journal of Medicine."},{"issue":"3","key":"155_CR62","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul, H., et al. (2021). CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. New England Journal of Medicine, 384(3), 252\u2013260.","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"155_CR63","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D., et al. (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine, 385(6), 493\u2013502.","journal-title":"New England Journal of Medicine"},{"issue":"9800","key":"155_CR64","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(10)61111-7","volume":"378","author":"JR Chapman","year":"2011","unstructured":"Chapman, J. R. (2011). The consequences of successful transplantation. Lancet, 378(9800), 1357\u20131359.","journal-title":"Lancet"},{"key":"155_CR65","doi-asserted-by":"crossref","unstructured":"Gilbert, F., & Lancelot, M. Incoming ethical issues for deep brain stimulation: when long-term treatment leads to a'new form of the disease'. Journal of Medical Ethics, p. medethics-2019-106052.","DOI":"10.1136\/medethics-2019-106052"},{"issue":"1","key":"155_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling, D. C., Pechmann, A., & Kirschner, J. (2020). Advances in treatment of spinal muscular atrophy-new phenotypes, new challenges, new implications for care. Journal of Neuromuscular Disease, 7(1), 1.","journal-title":"Journal of Neuromuscular Disease"},{"issue":"12","key":"155_CR67","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/mds.27235","volume":"32","author":"FM Weaver","year":"2017","unstructured":"Weaver, F. M., et al. (2017). Survival in patients with Parkinson\u2019s disease after deep brain stimulation or medical management. Movement Disorders, 32(12), 1756\u20131763.","journal-title":"Movement Disorders"},{"issue":"1","key":"155_CR68","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho, T., et al. (2013). THAOS-The transthyretin amyloidosis outcomes survey: Initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Current Medical Research and Opinion, 29(1), 63\u201376.","journal-title":"Current Medical Research and Opinion"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-021-00155-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-021-00155-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-021-00155-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:51:35Z","timestamp":1726015895000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-021-00155-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["155"],"URL":"https:\/\/doi.org\/10.1186\/s42466-021-00155-8","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MFD received financial reimbursement for consulting and advisory board activities and travel support to attend scientific meetings by Akcea Therapeuticals Inc., Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals. MFD further received research funding by Pfizer Pharmaceuticals (ASPIRE 2018). JM has no conflicts. KROD has received speaker fees from Eisai GmBH. EH received financial reimbursement for consulting and advisory board activities and\/or travel support by Akcea, Alnylam, and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}